It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OCUP’s FA Score shows that 1 FA rating(s) are green whileVYGR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OCUP’s TA Score shows that 3 TA indicator(s) are bullish while VYGR’s TA Score has 4 bullish TA indicator(s).
OCUP (@Biotechnology) experienced а +3.25% price change this week, while VYGR (@Biotechnology) price change was +16.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
VYGR is expected to report earnings on Mar 11, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
OCUP | VYGR | OCUP / VYGR | |
Capitalization | 33.8M | 319M | 11% |
EBITDA | -14.49M | -1.78M | 812% |
Gain YTD | -57.807 | -5.095 | 1,135% |
P/E Ratio | N/A | 21.67 | - |
Revenue | 16.4M | 144M | 11% |
Total Cash | 41.4M | 371M | 11% |
Total Debt | N/A | 46.9M | - |
OCUP | VYGR | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 80 | |
PRICE GROWTH RATING 1..100 | 86 | 46 | |
P/E GROWTH RATING 1..100 | 98 | 2 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OCUP's Valuation (21) in the null industry is somewhat better than the same rating for VYGR (59) in the Biotechnology industry. This means that OCUP’s stock grew somewhat faster than VYGR’s over the last 12 months.
OCUP's Profit vs Risk Rating (100) in the null industry is in the same range as VYGR (100) in the Biotechnology industry. This means that OCUP’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's SMR Rating (80) in the Biotechnology industry is in the same range as OCUP (96) in the null industry. This means that VYGR’s stock grew similarly to OCUP’s over the last 12 months.
VYGR's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for OCUP (86) in the null industry. This means that VYGR’s stock grew somewhat faster than OCUP’s over the last 12 months.
VYGR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for OCUP (98) in the null industry. This means that VYGR’s stock grew significantly faster than OCUP’s over the last 12 months.
OCUP | VYGR | |
---|---|---|
RSI ODDS (%) | N/A | 1 day ago83% |
Stochastic ODDS (%) | 1 day ago79% | 1 day ago90% |
Momentum ODDS (%) | 1 day ago84% | 1 day ago73% |
MACD ODDS (%) | 1 day ago76% | N/A |
TrendWeek ODDS (%) | 1 day ago82% | 1 day ago80% |
TrendMonth ODDS (%) | 1 day ago84% | 1 day ago81% |
Advances ODDS (%) | 30 days ago81% | 1 day ago77% |
Declines ODDS (%) | 8 days ago86% | 24 days ago84% |
BollingerBands ODDS (%) | 1 day ago90% | 1 day ago84% |
Aroon ODDS (%) | 4 days ago90% | 1 day ago88% |
A.I.dvisor indicates that over the last year, OCUP has been loosely correlated with NTLA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUP jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To OCUP | 1D Price Change % | ||
---|---|---|---|---|
OCUP | 100% | -0.78% | ||
NTLA - OCUP | 36% Loosely correlated | +1.94% | ||
SYRS - OCUP | 36% Loosely correlated | +2.09% | ||
ARRY - OCUP | 35% Loosely correlated | -2.77% | ||
SLNO - OCUP | 35% Loosely correlated | -1.83% | ||
VYGR - OCUP | 35% Loosely correlated | +1.26% | ||
More |
A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with PLRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then PLRX could also see price increases.
Ticker / NAME | Correlation To VYGR | 1D Price Change % | ||
---|---|---|---|---|
VYGR | 100% | +1.26% | ||
PLRX - VYGR | 45% Loosely correlated | -2.98% | ||
NTLA - VYGR | 45% Loosely correlated | +1.94% | ||
ELVN - VYGR | 44% Loosely correlated | -0.36% | ||
XNCR - VYGR | 43% Loosely correlated | -0.74% | ||
PRME - VYGR | 42% Loosely correlated | -4.04% | ||
More |